Eikonizo Therapeutics
Jacob Hooker is a co-founder of Eikonizo Therapeutics and a previous director of radiochemistry at the Athinoula A. Martinos Center for Biomedical Imaging. Jacob has also worked as an associate editor for the ACS Chemical Neuroscience journal and as an associate professor of radiology at Harvard Medical School. Prior to their current position, Hooker was a scientific director at the Lurie Center for Autism and a Phyllis and Jerome Lyle Rappaport MGH Research Scholar.
Jacob Hooker has a Ph.D. in Chemistry from the University of California, Berkeley and a BS in Chemistry from North Carolina State University.
Jacob Hooker works with Tonya Gilbert - Director, Translational Research, Richard Margolin - Chief Medical Officer, and Florence Wagner - Director, Medicinal Chemistry. Their manager is Janice Kranz, CEO & Co-Founder.
Eikonizo Therapeutics
Eikonizo is developing life-changing therapies by creating brain-penetrant small molecules and deploying in vivo target engagement techniques to accelerate the identification of therapeutics. Their first program is focused on a disease-modifying therapeutics for neurodegenerative diseases.